Hormonal
Orlistat treatment for 3 months in women with PCOS produces a statistically significant reduction in body weight and serum testosterone levels, with weight loss effects being greater than those observed with metformin.
If you have PCOS and are looking to lose weight and lower testosterone, Orlistat (120mg, 3x daily) may be more effective for weight loss than Metformin over a short 3-month period, while still effectively lowering testosterone. Ensure you follow the dietary changes recommended during the initial 8-week period to maximize results and minimize side effects.
Treatment with orlistat for 3 months led to a 4.7% reduction in body weight, a more significant loss than was observed in metformin-treated women (1.0%). Serum testosterone levels declined significantly in both groups.
Why this rating
Randomized, open-label study, but small sample size (n=21) and short duration (3 months).
Source
A Potential Decline in Life Expectancy in the United States in the 21st Century
S. Jay Olshansky et al. · Obstetrical & Gynecological Survey · 2005
DOI 10.1097/01.ogx.0000167407.83915.e7
More from this paper
- Microwave endometrial ablation (MEA) results in higher patient satisfaction and lower rates of subsequent hysterectomy compared to transcervical resection of the endometrium (TCRE) over a 5-year follow-up.Good
- Intra-uterine levonorgestrel administration provides long-term symptom relief for symptomatic endometriosis, with pain and blood loss decreasing significantly over 3 years, though device retention rates drop over time due to irregular bleeding.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →